Back

DIABETES SPOTLIGHT: Changing the Landscape of Diabetes

MedImpact Investigates the Impact of Oral Semaglutide and Diabetes Market Trends

BY: KAREN WATKINS & SUSAN TRIEU
 

With the potential to change the landscape of diabetes treatment, oral semaglutide ushers in the next generation of diabetes care with its anticipated FDA approval in September.

First approved as a weekly injectable by the FDA in late 2018 under the brand name Ozempic, semaglutide falls in the blockbuster class of drugs known as glucagon-like peptide-1s (GLP-1s).

A non-insulin medication, GLP-1 receptor agonists treat Type 2 diabetes by lowering blood glucose levels and aiding in weight loss. They also can have positive effects on blood pressure, cholesterol levels, and beta-cell function.

Oral semaglutide will further increase the already rapidly growing market share of the entire GLP-1 class, potentially reaching $3 to $6 billion in peak annual blockbuster sales.

This growth will primarily occur due to a utilization shift from oral sodium-glucose co-transporter-2 inhibitors (SGLT2) and DPP-4 inhibitors (DPP4), although some patients may stick with other oral options due to drug-specific benefits, including SGLT2s in heart failure patients and DPP4s in frail patients.

Analysts also anticipate that an oral option of semaglutide will induce shifts from injectable GLP-1sas some patients will prefer it over injections.

Besides the blood glucose and weight-loss advantage, semaglutide has another positive feature: proven cardiovascular safety. A second application for cardiovascular risk reduction is slated for FDA approval in January 2020.

The Nation’s Diabetes Crisis

An estimated 30.3 million Americans — 9.4% of the U.S. population — have either type 2 diabetes or undiagnosed diabetes.1 And as many as 1 in 3 adults could have diabetes by 2050 if the current health crisis continues, according to recent CDC reports.The economic impact is also staggering: The estimated costs of diagnosed diabetes reached $327 billion in 2017, including $237 billion in direct medical costs and $90 billion in reduced productivity.Total annual medical and economic costs related to diabetes will increase 53% to more than $622 billion by 2030.4

CASE STUDY SPOTLIGHT

Learn how MedImpact is partnering with Bon Secours Mercy Health to help combat the diabetes epidemic.

To see how we can help you achieve significant clinical and financial results, download the full case study here.

Clinical Indication & Efficacy

Based on results from 10 PIONEER clinical trials, which involved more than 9,500 adults with Type 2 diabetes, oral semaglutide was highly effective in controlling blood glucose and body weight compared with new generation diabetes drugs, including DPP-4 inhibitor Januvia (sitagliptin); SGLT2 inhibitor Jardiance (empagliflozin); and daily injectable GLP-1 agonist Victoza (liraglutide).

Safety and tolerability of oral semaglutide is in line with injectable members of the class, with the exception of higher rates of nausea, vomiting, and discontinuation at the highest dose. GI side effects usually wane after 16 weeks of treatment. Until now, developing an oral delivery has been a major challenge due to rapid enzymatic breakdown and poor intestinal protein absorption in the GI tract, requiring advanced technology to improve absorption of the drug to enable oral delivery.

Read more about new pipeline agents and diabetes trends in our Annual Trend Report’s Spotlight on Diabetes.

Download the 2018 Annual Trend Report

Check MedConnect regularly for more drug trend insights from our 2018 MedImpact Annual Trend Report.

1 National Institutes of Health:  https://www.niddk.nih.gov/health-information/health-statistics/diabetes-statistics
2   CDC: https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html
National Institutes of Health: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278808/
American Diabetes Association: http://www.diabetes.org/advocacy/news-events/cost-of-diabetes.html
IQVIA: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/medicine-use-and-spending-in-the-us-a-review-of-2017-and-outlook-to-2022.pdf?_=1560467228282

  • Email